Eli Lilly & Co.
Moat Score — Eli Lilly & Co.
Total Moat Score
18 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Patent-protected blockbuster molecules (tirzepatide), FDA approval barriers, and a deep R&D/clinical-trial pipeline create some of the strongest intangible-asset protection of any industry, evidenced by Lilly's first-mover efficacy edge in GLP-1/GIP therapies. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Massive manufacturing scale and years of accumulated capacity investment in incretin production give Lilly real cost and supply advantages, though its business model is fundamentally about innovation rents rather than being a low-cost producer. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Patent exclusivity has historically enabled strong pricing on branded therapies like Mounjaro and Zepbound, though escalating U.S. political scrutiny of drug pricing and GLP-1 list prices is a real constraint. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical products do not become more valuable as more patients use them; there is no network dynamic. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once patients and physicians settle into a treatment regimen and insurance formulary, there is some inertia to switching, but generic/biosimilar competition and rival GLP-1 drugs (Novo Nordisk's semaglutide) show switching does occur when alternatives are compelling. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 4 / 5 | The billions of dollars and years of clinical development required to bring a new blockbuster drug to market create a high barrier that only a handful of global pharma majors can clear, protecting incumbents' economics. |